Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients (Alpaca)
Chemotherapy is a vital treatment for breast cancer, but certain common chemotherapy drugs, called anthracyclines, can sometimes cause unwanted side effects on the heart and blood vessels. Over time, this can lead to heart muscle weakness or poor circulation. This clinical trial is testing a daily tablet called dapagliflozin (also known as Forxiga) to see if it can protect the heart while women undergo chemotherapy. Dapagliflozin is already safely used to treat diabetes and heart failure, but researchers want to know if it can prevent heart damage before it starts. Participants will take either dapagliflozin or a harmless dummy pill (placebo) alongside their usual cancer care. Doctors will check their heart health, blood vessels, and general fitness over one year to compare how well both groups do.
At a glance
What is this study about?
Chemotherapy medicines called anthracyclines are very effective at treating breast cancer. However, doctors know that they can sometimes cause strain on the heart and blood vessels. In some women, this can lead to long-term heart weakness. Finding ways to protect the heart during cancer care is essential so that patients can complete their cancer treatment safely without developing new health problems.
This study, named Alpaca, is testing a medicine called dapagliflozin (brand name Forxiga). This drug is already widely prescribed in the UK to help people manage type 2 diabetes and heart conditions. Researchers believe it may also shield the heart muscle and keep blood vessels healthy and flexible while a person is receiving chemotherapy.
During the trial, half of the participants will take a daily dapagliflozin tablet, and the other half will take an identical dummy tablet (placebo). Neither you nor your doctor will know which one you are taking. Throughout the year-long study, doctors will closely track your heart function, general well-being, and blood markers to see whether dapagliflozin truly provides extra protection.
Key takeaways
- Tests whether the drug dapagliflozin can protect the heart from chemotherapy damage.
- Open to women aged 18 and over having anthracycline chemotherapy for breast cancer.
- Involves taking one tablet each day (either dapagliflozin or a placebo) for up to one year.
- Includes non-invasive heart scans, blood vessel checks, and standard blood tests.
- Participation is voluntary and will not interrupt your planned cancer treatment.
Who may be eligible?
This trial is designed for adult women who have been diagnosed with breast cancer and are scheduled to receive chemotherapy that includes an anthracycline drug.
To be considered, you must be aged 18 or older. Because this study focuses specifically on protecting the heart during this particular type of chemotherapy, you can only join if your planned treatment includes anthracyclines.
Your cancer team will also review your overall health, current medications, and medical history to make sure taking part is completely safe for you. If you have severe kidney problems or certain other health conditions, this trial might not be suitable.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am a woman aged 18 or older.
- I have been diagnosed with breast cancer.
- My cancer team plans to treat me with an anthracycline chemotherapy drug.
- I am willing to take a daily study tablet for up to a year.
- I can attend regular hospital visits for heart scans and blood tests.
What does participation involve?
If you take part, you will be randomly assigned to take either one dapagliflozin (10 mg) tablet or one matching placebo tablet once a day. You will take this alongside your normal breast cancer treatment.
The study lasts for about one year (52 weeks). During this time, you will attend hospital visits to monitor your health. These checks will include heart scans (ultrasounds called echocardiograms) to see how well your heart pumps, simple arm cuff tests to measure how well your blood vessels widen, and routine blood tests.
You will also do a gentle six-minute walking test to measure your stamina, and you will be asked to fill in short questionnaires about your daily energy levels and quality of life at different points during the study.
Potential risks and benefits
Locations (1)
- —UnverifiedSlovenia
Common questions
Will taking part affect my breast cancer treatment?
No. You will continue to receive your planned chemotherapy and cancer care exactly as recommended by your oncology team.
What is a placebo?
A placebo is a harmless dummy tablet that looks identical to the real medicine but contains no active drug. It helps researchers fairly test whether the active drug makes a real difference.
Can I choose whether I get the real drug or the placebo?
No. A computer assigns you to a group at random. Neither you nor your doctors will know which tablet you are taking until the study ends.
Are the heart tests painful?
No. The tests are non-invasive and painless. They mainly involve ultrasound scans of your chest, blood pressure cuffs on your arm, and standard blood tests.
What happens if I change my mind during the study?
You can leave the trial at any point, for any reason. Your doctors will continue to support you and provide your normal cancer care without any disruption.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.